Cyclodextrins: Application in different routes of drug administration

Acta Pharmaceutica

Volumn 55, Issue 2, 2005, Pages 139-156

  Shimpi, Shyam ^a   Chauhan, Bhaskar ^a   Shimpi, Prajakta ^b  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b Department of Pharmacology   (India)

Author keywords

Cyclodextrins; Nasal drug delivery; Ophthalmic drug delivery; Oral drug delivery; Rectal drug delivery; Release mechanism; Transdermal drug delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 4 HYDROXYBENZOIC ACID ESTER; ALPHA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BETAMETHASONE; BUSERELIN; CALCITONIN; CHLORPROMAZINE; CINNARIZINE; CYCLODEXTRIN DERIVATIVE; DIHYDROERGOTAMINE; DILTIAZEM; ESTRADIOL; FLURBIPROFEN; GAMMA CYCLODEXTRIN DERIVATIVE; GLUCAGON; IMIDAZOLE; INSULIN; LEUPRORELIN; MELATONIN; MIDAZOLAM; MORPHINE; NAPROXEN; NIFEDIPINE; PILOCARPINE; PIRODAVIR; PROGESTERONE; TIMOLOL; UNINDEXED DRUG;

AQUEOUS SOLUTION; COMPLEX FORMATION; DILUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; DRUG USE; DRY NOSE; EYE IRRITATION; HUMAN; IONIC STRENGTH; NONHUMAN; PRECIPITATION; REVIEW; RHINOVIRUS; SIDE EFFECT;

EID: 22244468039     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. J. Szejtli, Introduction and general overview of cyclodextrin chemistry, Chem. Rev. 98 (1998) 1743-1753.
2. Comprehensive Supramolecular Chemistry (Eds J. Szejtli and T. Osa), Vol. 3, Pergamon Press, Oxford 1996, pp. 57-127.
3. J. Pitha, Cyclodextrin Derivatives with Enhanced Solubility Power and Lower Toxicity, Proceedings of the Ninth International Symposium on Cyclodextrins (Ed. L. J. J. Torres), May 31-June 3, 1998, Santiago de Compostela, Spain, Kluwer Academic Publisher, Dordrecht, 210-215.
4. B. Casu, M. Reggiani and G. Vigevani, Conformation of O-methylated amylose and cyclodextrins, Tetrahedron 242 (1967) 803-821.
5. J. Szejtli, A. Liptak, I. Jodal and A. Neszelyi, Synthesis and C-NMR spectroscopy of methylated β-CD, Starch/Starke 32 (1980) 165-169.
6. K. Uekama, Pharmaceutical application of methylated cyclodextrins, Pharm. Int. 6 (1985) 61-65.
7. L. Szente and J. Szejtli, Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development, Adv. Drug Del. Rev. 36 (1999) 17-28.
8. T. Loftsson and M. E. Brewster, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025.
9. D. Teshimna, K. Otsubo, S. Higuchi, F. Hirayamna, K. Uekama and T. Aoyama, Effects of cyclodextrins on degradations of emetine and cephaeline in aqueous solution, Chem. Pharm. Bull. 37 (1989) 1591-1594.
10. J. Mielcarek, Photochemical stability of the inclusion complexes of nicardipine with α-, γ-cyclodextrin, methyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin in solid state and in solution, Pharmazie 51 (1996) 477-479.
11. G. Piel, T. Van Hees, B. Evard and L. A. Delattre, Comparative pharmacokinetic study of intravenous solutions containing miconazole with or without cyclodextrins, Proceedings of the Ninth International Symposium on Cyclodextrins (Ed. L. J. J. Torres), May 31-June 3, 1998, Santiago de Compostela, Spain, Kluwer Academic Publisher, Dordrecht, pp. 223-226.
12. K. Okimoto, R. A. Rajewski, K. Uekama, J. A. Jona and V. J. Stella, The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins, Pharm. Res. 13 (1996) 256-264.
13. V. J. Stella, V. M. Rao, E. A. Zannou and V. Zia, Mechanisms of drug release from cyclodextrin complexes, Adv. Drug Del. Rev. 36 (1999) 3-16.
14. J. Van Stain, S. D. Feyter, F. C. De Schryever and C. H. Evans, 2-Naphthol complexation by β-cyclodextrin: influence of added short linear alcohols, J. Phys. Chem. 100 (1996) 19959-19966.
15. T. Tokomura, Y. Tsushima, M. Kayano, Y. Machida and T. Nagai, Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent, J. Pharm. Sci. 74 (1985) 496-497.
16. T. Tokomura, M. Nanba, Y. Tsushima, K. Tatsuishi, M. Kayano, Y. Machida and T. Nagai, Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent, J. Pharm. Sci. 75 (1986) 391-394.
17. H. W. Frijlink, E. J. F. Franssen, A. C. Eissens, R. Oosting, C. F. Lerk and D. K. F. Meijer, The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat, Pharm. Res. 8 (1991) 380-384.
18. R. A. Rajewski and V. J. Stella, Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery, J. Pharm. Sci. 85 (1996) 1142-1169.
19. K. Jarvinen, T. Jarvinen, D. O. Thompson and V. J. Stella, The effect of a modified β-cyclodextrin, SBE4-β-CD, on the aqueous stability and ocular absorption of pilocarpine, Curr. Eye Res. 13 (1994) 897-905.
20. T. Backensfeld, B. W. Muller and K. Kolter, Interaction of NSA with cyclodextrins and hydroxypropyl cyclodextrin derivatives, Int. J. Pharm. 74 (1991) 85-93.
21. F.-Y. Liu, D. O. Kildsig and A. K. Mitra, Cyclodextrin/weak electrolyte complexation: interpretation and estimation of association constants from phase solubility diagrams, Pharm. Res. 9 (1992) 1671-1672.
22. T. Loftsson and M. E. Brewster, Pharmaceutical application of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci. 85 (1996) 1017-1025.
23. Y. Inoue, T. Hakushi, Y. Liu, L.-H. Tong, B. J. Shen and D. S. Jin, Thermodynamics of molecular recognition by cyclodextrins 1. Calorimetric titration of inclusion complexation of napthalesulfonates with α, β- and γ-cyclodextrins: enthalpy-entropy compensation, J. Am. Chem. Soc. 115 (1993) 475-481.
24. T. Loftsson and E. Stefansson, Effect of cyclodextrins on topical drug delivery to the eye, Drug Dev. Ind. Pharm. 23 (1997) 473-481.
25. D. Duchene and D. Wouessidjewe, Pharmaceutical and Medical Applications of Cyclodextrins, in Polysaccharides in Medical Applications (Ed. S. Dumitriu), Marcel Dekker, New York 1996, pp. 575-602.
26. P. Suhonen, T. Jarvinen, K. Lehmussaari, T. Reunamaki and A. Urtti, Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eye drop, Pharm. Res. 12 (1995) 529-533.
27. T. Jarvinen, K. Jarvinen, A. Urtti, D. Thompson and V. J. Stella, Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eye drops improves the tolerability of a topically applied pilocarpine prodrug in rabbits, J. Ocular Pharmacol. Ther. 11 (1995) 95-106.
28. P. Jarho, K. Jarvinen, A. Urtti, V. J. Stella and T. Jarvinen, Modified β-cyclodextrin (SBE7-β-CD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits, J. Pharm. Pharmacol. 48 (1996) 263-269.
29. Y. Ikejiri, F. Tokomochi, S. Sameshima and M. Kimura, Antiallergic Composition for Ophthalmic or Nasal Use, Eur. Pat. 0,605,203, 06 July 1994; ref. Chem. Abstr. 121 (1994) 141690d.
30. th ed., Drug Information for the Health Care Professional, United States Pharmacopoeial Convention, Rockville 1990, pp. 589-590.
31. V. H. L. Lee and J. R. Robinson, Topical ocular drug delivery: recent developments and future challenges, J. Ocular Pharmacol. 2 (1986) 67-108.
32. K. Jarvinen, T. Jarvinen, D. O. Thompson and V. Stella, The effect of modified β-cyclodextrin, SBE4-β-CD, on the aqueous solubility and ocular absorption of pilocarpine, Curr. Eye Res. 13 (1994) 891-905.
33. N. M. Davies, G. Wang and I. G. Tucker, Evaluation of a hydrocortisone/hydroxypropyl-β-cyclodextrin solution for ocular drug delivery, Int. J. Pharm. 156 (1997) 201-209.
34. G. S. Tirucherai and A. K. Mitra, Effect of hydroxypropyl beta-cyclodextrin complexion on aqueous solubility, stability and corneal permeation of acyl ester prodrugs of ganciclovir, AAPS PharmSciTech. 4 (2003) Article, 45.
35. K. A. Freedman, J. W. Klein and C. E. Crosson, Beta-cyclodextrins enhance bioavailability of pilocarpine, Curr. Eye Res. 12 (1993) 641-647.
36. J. C. Lang and M. M. Stiemke, Biological Barriers to Ocular Delivery, in Ocular Therapeutics and Drug Delivery. A Multi-disciplinary Approach (Ed. I. K. Reddy), Technomic Publishing, Lancaster 1996, pp. 51-132.
37. T. Loftsson, H. Fridriksdottir, S. Thorisdottir and E. Stefansson, The effect of hydroxypropyl methyl cellulose on release of dexamethazone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations, Int. J. Pharm. 104 (1994) 181-184.
38. T. Loftsson, H. Fridriksdottir, S. Thorisdottir, E. Stefansson, A. M. Sigurdardottir, O. Gudmundsson and T. Sigthorsson, 2-Hydroxypropyl-β- cyclodextrin in topical carbonic anhydrase inhibitor formations, Eur. J. Pharm. Sci. 1 (1994) 175-180.
39. S. J. Lehner, B. W. Muller and J. K. Seydel, Effect of hydroxypropyl-β-cyclodextrin on the antimicrobial action of preservatives, J. Pharm. Pharmacol. 46 (1994) 186-191.
40. T. Loftsson, O. Stefansdottir, H. Fridriksdottir and O. Gudmundsson, Interaction between preservatives and 2-hydroxypropyl-β-cyclodextrin, Drug Dev. Ind. Pharm. 18 (1992) 1477-1484.
41. S. J. Lehner, B. W. Muller and J. K. Seydel, Interactions between p-hydroxybenzoic acid esters and hydroxypropyl-β-cyclodextrins and their antimicrobial effect against Candida albicans, Int. J. Pharm. 93 (1993) 201-208.
42. K. Asai, M. Morishita, H. Katsuta, S. Hosoda, K. Shinomiya, M. Noro, T. Nagai and K. Takayama, The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa, Int. J. Pharm. 246 (2002) 25-35.
43. W. A. J. J. Hermens, C. W. J. Belder, J. M. W. M. Merkus, P. M. Hooymans, J. Verhoef and F. W. H. M. Merkus, Intranasal estradiol administration to oophorectomized women, Eur. J. Obstet. Gynecol. Reprod. Biol. 40 (1991) 35-41.
44. W. A. J. J. Hermens, C. W. J. Belder, J. M. W. M. Merkus, P. M. Hooymans, J. Verhoef and F. W. H. M. Merkus, Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study, Eur. J. Obstet. Gynecol. Reprod. Biol. 43 (1992) 65-70.
45. T. Kondo, K. Nishimura, M. Hirata, T. Irie and K. Uekama, Effects of cyclodextrins on nasal absorption and analgesic activity of opioids in rats, Proceedings of the Eighth International Symposium on Cyclodextrins (Eds. J. Szejtli and L. Szente), March 30-April 2, 1996, Budapest, Kluwer Academic Publishers, Dordrecht, pp. 387-390.
46. T. Loftsson, H. Guomundsdottir, J. F. Sigurjonsdottir, H. H. Sigurosson, S. D. Sigfusson, M. Masson and E. Stefansson, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray, Int. J. Pharm. 212 (2001) 29-40.
47. E. Marttin, S. G. Romeijn, J. C. Verhoef and F. W. H. M. Merkus, Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits, J. Pharm. Sci. 86 (1997) 802-807.
48. W. A. J. J. Hermens, M. J. M. Deurloo, S. G. Romeijn, J. C. Verhoef and F. W. H. M. Merkus, Nasal absorption enhancement of 17-β-oestradiol by dimethyl-β-cyclodextrin in rabbits and rats, Pharm. Res. 7 (1990) 500-503.
49. N. G. M. Schipper, W. A. J. J. Hermens, S. G. Romeijn, J. Verhoef and F. W. H. M. Merkus, Nasal absorption of 17-β-estradiol and progesterone from a dimethyl-β-cyclodextrin inclusion formulation in rats, Int. J. Pharm. 64 (1990) 61-66.
50. F. G. Hayden, K. Andries and P. A. J. Jansen, Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection, Antimicrob. Agents Chemother. 36 (1992) 727-732.
51. F. W. H. M. Merkus, Nasal Melatonin Compositions, Eur. Pat. 0,867,181, 30 September 1998; ref. Chem. Abstr. 129 (1998) 281008e.
52. K. Matsubara, K. Abe, T. Irie and K. Uekama, Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats, J. Pharm. Sci. 84 (1995) 1295-1300.
53. A. Adjei, D. Sundberg, J. Miller and A. Chun, Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res. 9 (1992) 244-249.
54. N. G. M. Schipper, J. C. Verhoef, S. G. Romeijn and F. W. H. M. Merkus, Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin, Calcif. Tissue Int. 56 (1995) 280-282.
55. F. M. Sakr, Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations, Int. J. Pharm. 132 (1996) 189-194.
56. N. G. M. Schipper, S. G. Romeijn, J. C. Verhoef and F. W. H. M. Merkus, Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations, Pharm. Res. 10 (1993) 682-686.
57. Y. Watanabe, Y. Matsumoto, K. Kawamoto, S. Yazawa and M. Matsumoto, Enhancing effects of cyclodextrins on nasal absorption of insulin and its duration in rabbits, Chem. Pharm. Bull. 40 (1992) 3100-3104.
58. F. Glomot, L. Benkerrour, D. Duchene and M. C. Poelman, Improvement in availability and stability of a dermacorticoid by inclusion in β-cyclodextrin, Int. J. Pharm. 46 (1988) 49-55.
59. 1 through hairless mouse skin: combined use of carboxymethyl-ethyl-β-cyclodextrin and penetration enhancers, J. Pharm. Pharmacol. 44 (1992) 119-121.
60. H. Adachi, T. Irie, K. Uekama, T. Manako, T. Yano and M. Saita, Combination effects of O-carboxymethyl-O-ethyl-β-cyclodextrin and penetration enhancer HPE-101 on transdermal delivery of prostaglandin E1 in hairless mice, Eur. Pharm. Sci. 1 (1993) 117-123.
61. M. Otagiri, T. Fujinaga, A. Sakai and K. Uekama, Effects of β- and γ-cyclodextrins on release of betamethasone from ointment bases, Chem. Pharm. Bull. 32 (1984) 2401-2405.
62. K. Uekama, M. Otagiri, A. Sakai, T. Irie, N. Matsuo and Y. Matsuoka, Improvement in the percutaneous absorption of beclomethasone dipropionate by γ-cyclodextrin complexation, J. Pharm. Pharmacol. 37 (1985) 532-535.
63. K. Uekama, K. Masaki, K. Arimori, T. Irie and F. Hirayama, Effects of β- and dimethyl-β-cyclodextrins on release and percutaneous absorption behaviors of prednisolone from some ointment bases, Yakugaku Zasshi 107 (1987) 449-456;
64. ref. Chem. Abstr. 107 (1987) 120965t.
65. H. Arima, H. Adachi, T. Irie and K. Uekama, Improved drug delivery through the skin by hydrophilic β-cyclodextrins. Enhancement of anti-inflammatory effect of 4-biphenylylacetic acid in rats, Drug Invest. 2 (1990) 155-161.
66. S. Z. Lin, D. Wouessidjewe, M. C. Poelman and D. Duchene, In-vivo evaluation of indomethacin/cyclodextrin complexes gastrointestinal tolerance and dermal anti-inflammatory activity, Int. J. Pharm. 106 (1994) 63-67.
67. T. Loftsson, H. Fririksdottir, G. Ingvarsdottir, B. Jonsdottir and A. M. Siguraraottir, The influence of 2-hydroxypropyl-β-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone, Drug Dev. Ind. Pharm. 20 (1994) 1699-1708.
68. T. Loftsson and A. M. Sigurardottir, The effect of polyvinyl pyrrolidone and hydroxypropyl methyl cellulose on hydroxypropyl-β-cyclodextrin complexation of hydrocortisone and its permeability through hairless mouse skin, Eur. J. Pharm. Sci. 2 (1994) 297-301.
69. T. Loftsson, H. Fririksdottir, S. Thorisdottir and E. Stefansson, The effect of hydroxypropyl methyl cellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations, Int. J. Pharm. 104 (1994) 181-184.
70. M. Umemura, H. Ueda, K. Tomono and T. Nagai, Effect of diethyl-β-cyclodextrin on the release of nitroglycerin from formulations, Drug Design Deliv. 6 (1990) 297-310.
71. K. Tomono, H. Gotoh, M. Okamura, M. Horioka, H. Ueda and T. Nagai, Effect of β-cyclodextrins on sustained release of nitroglycerin from ointment bases, Yakuzaigaku 51 (1991) 22-28;
72. ref. Chem. Abstr. 115 (1991) 142119n.
73. J. Y. Legendre, I. Rault, W. Luijten, I. Demuynck and S. Horvath, Effects of β-cyclodextrins on skin: Implications for the transdermal delivery of piribedil and a novel cognition enhancing drug, S-9977, Eur. J. Pharm. Sci. 3 (1995) 311-322.
74. S. D. Roy and G. J. De, Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin, Int. J. Pharm. 110 (1994) 137-145.
75. T. Hoshino, K. Ishida, T. Irie, K. Uekama and T. Ono, Alleviation of chlorpromazine photosensitized contact dermatitis by β-cyclodextrin derivatives and their possible mechanisms, Proceedings of Nineteenth Symposium on Drug Metabolism and Action, October 27-28, 1988, Osaka, J. Pharmacobio-dyn. 12 (1989) S-70.
76. K. Uekama, T. Irie, M. Sunada, M. Otagiri, Y. Arimatsu and S. Nomura, Alleviation of prochlorperazine induced primary irritation of skin by cyclodextrin complexation, Chem. Pharm. Bull. 30 (1982) 3860-3862.
77. H. Matsuda and H. Arima, Cyclodextrins in transdermal and rectal delivery, Adv. Drug Del. Rev. 36 (1999) 81-99.
78. T. Takahashi, I. Kagami, K. Kitamura, Y. Nakanishi and Y. Imasato, Stabilization of AD-1590, a non-steroidal anti-inflammatory agent, in suppository bases by β-cyclodextrin complexation, Chem. Pharm. Bull. 34 (1986) 1770-1774.
79. H. Arima, T. Kondo, T. Irie and K. Uekama, Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble β-cyclodextrin derivatives and formulation as oleaginous suppository, J. Pharm. Sci. 81 (1992) 1119-1125.
80. T. Kondo, T. Irie and K. Uekama, Combination effects of a-cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits, Biol. Pharm. Bull. 19 (1996) 280-286.
81. Y. Watanabe, Y. Matsumoto, M. Seki, M. Takase and M. Matsumoto, Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits, Chem. Pharm. Bull. 40 (1992) 3042-3047.
82. Y. Watanabe, M. Kiriyama and R. Ito, Pharmacodynamics and pharmacokinetics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after administration of a rectal dosage vehicle, Biol. Pharm. Bull. 19 (1996) 1059-1063.
83. H. Arima, T. Kondo, T. Irie, F. Hirayama, K. Uekama, T. Miyaji and Y. Inoue, Use of water-soluble β-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenyl-acetic acid in rectal delivery, Yakugaku Zasshi 112 (1992) 65-72;
84. ref. Chem. Abstr. 116 (1992) 181015r.
85. M. E. Brewster, W. R. Anderson, K. S. Estes and N. Bodor, Development of aqueous patenteral formulations for carbamazepine through the use of modified cyclodextrins, J. Pharm. Sci. 80 (1991) 380-383.
86. M. T. Esclusa-Diaz, M. Gayo-Otero, M. B. Perez-Marcos, J. L. Vila-Jato and J. J. Torres Labandeira, Preparation and evaluation of ketoconazole-β- cyclodextrin multicomponent complexes, Int. J. Pharm. 142 (1996) 183-187.
87. M. Pedersen, S. Bjerregaard, J. Jacobson, A. R. Larsen and A. M. Sorensen, An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example, Int. J. Pharm. 165 (1998) 57-68.
88. K. Uekama, T. Fujinaga, F. Hirayama, M. Otagiri, M. Yamasaki, H. Seo, T. Hashimoto and M. Tsuruoka, Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation, J. Pharm. Sci. 72 (1983) 1338-1341.
89. C. J. Betlach, M. A. Gonzalez, B. C. Mckiernan, C. Neff-Davis and N. Bodor, Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex, J. Pharm. Sci. 82 (1993) 1058-1060.
90. 1 by maltosyl-β-cyclodextrin in lyophilized formulation, Chem. Pharm. Bull. 40 (1992) 747-751.
91. T. Jarvinen, K. Jarvinen, N. Schwarting and V. J. Stella, β-Cyclodextrin derivatives, SBE-β-CD and HB-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs, J. Pharm. Sci. 84 (1995) 295-299.
92. T. Horikawa, F. Hirayama and K. Uekama, In-vivo and in-vitro correlation for delayed-release behavior of a molsidomine/O-carboxymethyl-O-ethyl-β- cyclodextrin complex in gastric acidity-controlled dogs, J. Pharm. Pharmacol. 47 (1995) 124-127.
93. Y. Horiuchi, F. Hirayama and K. Uekama, Slow-release characteristics of diltiazem from ethylated β-cyclodextrin complexes, J. Pharm. Sci. 79 (1990) 128-132.
94. Z. Wang, F. Hirayama and K. Uekama, In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-β-cyclodextrin and hydroxypropyl celluloses in dogs, J. Pharm. Pharmacol. 46 (1994) 505-507.
95. K. Okimoto, R. A. Rajewski, K. Uekama, J. A. Jana and V. J. Stella, The interaction of charged and uncharged drugs with neutral (HB-β-CD) and anionically charged (SBE-β-CD) β-cyclodextrins, Pharm. Res. 13 (1996) 256-264.